Share

July 26, 2016; 87 (4) Editorial

Treating myasthenia on consensus guide: Helpful and challenging but still unfinished business

Marinos C. Dalakas
First published June 29, 2016, DOI: https://doi.org/10.1212/WNL.0000000000002796
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
319

Share

Article Information

vol. 87 no. 4 350-351
DOI: 
https://doi.org/10.1212/WNL.0000000000002796
PubMed: 
27358340
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published June 29, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Marinos C. Dalakas, MD
  1. Marinos C. Dalakas, MD
    2. Scientific Advisory Boards:

    1. Serves on the CIDP steering committee for Novartis and on DSMB for Baxalta

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Baxter, CSL, Servier, Novartis, Hoffman LaRoch, Merck/Serono

    Editorial Boards:

    1. 1. Neurology, editorial board (5 years, not compensated); 2)BMC Neurology (Section Editor, 5 years not compensated); 3) Acta Myologica, editorial board (5 years, not compensated); 5)Acta Neurologica Scandinavica editorial board ( 5 years, not compensated); 6)Therapeutic Advances in Neurology (Associate Editor; 4 years, compensated)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Therapath, Grifols, Novartis, Baxter, Octapharma, Hoffman LaRoch, Servier, CSL

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Received Institutional support to Thomas Jefferson University Neurology department or to Neuroimmunology Unit, University of Athens Medical School for research and education from: Merck-Serono, Genzyme, Novartis, Guillain-Barre/CIDP Foundation, Dysimmune diseases Foundation, CSL, Biogen and Newfactor

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology, Thomas Jefferson University, Philadelphia, PA; and Neuroimmunology Unit, University of Athens Medical School, Greece.
  1. Correspondence to Dr. Dalakas: marinos.dalakas{at}jefferson.edu
View Full Text

Article usage

Article usage: June 2016 to January 2021

AbstractFullPdfSource
Jun 2016100013Highwire
Jul 201683547139Highwire
Aug 20162192240Highwire
Sep 201675422Highwire
Oct 20168637Highwire
Nov 201659610Highwire
Dec 20163475Highwire
Jan 20174524Highwire
Feb 20174244Highwire
Mar 20172600Highwire
Apr 20172752Highwire
May 20172902Highwire
Jun 20173012Highwire
Jul 20172122Highwire
Aug 20171623Highwire
Sep 20172214Highwire
Oct 20171914Highwire
Nov 20171300Highwire
Dec 20173102Highwire
Jan 20182621Highwire
Feb 20182431Highwire
Mar 20182311Highwire
Apr 20182711Highwire
May 20181513Highwire
Jun 20182422Highwire
Jul 20181604Highwire
Aug 20182132Highwire
Sep 20183321Highwire
Oct 20182931Highwire
Nov 20183723Highwire
Dec 20183221Highwire
Jan 20192912Highwire
Feb 20192813Highwire
Mar 20191322Highwire
Apr 20192611Highwire
May 20194423Highwire
Jun 20192310Highwire
Jul 20191663Highwire
Aug 20193175Highwire
Sep 20191002Highwire
Oct 20192451Highwire
Nov 20192900Highwire
Dec 20191700Highwire
Jan 20201520Highwire
Feb 20202302Highwire
Mar 20201401Highwire
Apr 20201100Highwire
May 2020711Highwire
Jun 2020700Highwire
Jul 20201453Highwire
Aug 20202411Highwire
Sep 20203000Highwire
Oct 20203600Highwire
Nov 20202541Highwire
Dec 20201522Highwire
Jan 20212510Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me